Functional Genetics, Epigenetics, and Non coding RNAs in Drug Addiction (R03) | Apply Online

Frequently Asked Questions (FAQs)

What is the official title and number of this funding opportunity?

The opportunity is titled "Functional Genetics, Epigenetics, and Non coding RNAs in Drug Addiction (R03)" and the Funding Opportunity Number (FOA) is PA-11-035.

Who is the sponsoring agency?

The sponsoring agency is the National Institutes of Health (NIH).

What type of funding is this (grant or contract)?

This is a grant opportunity (not a contract).

What CFDA program is this opportunity associated with?

It is aligned with CFDA 93.279, Drug Abuse and Addiction Research Programs.

What is the main purpose of this FOA?

The FOA is focused on moving beyond gene discovery and statistical associations to test what genetic and genomic findings actually do in the biology of drug addiction. It supports small, targeted projects that validate candidate genes, variants, epigenetic marks, or non-coding RNAs and then clarify the molecular pathways through which they affect addiction-related biology and behaviors.

What problem is this program trying to address?

Large-scale genetic and genomic studies have produced many candidates that appear associated with drug addiction, but association alone does not explain mechanism. This program aims to fund studies that determine whether these candidates are truly causal or biologically meaningful and, if so, how they work.

What research directions does the FOA emphasize?

The announcement highlights two main directions: (1) functional validation to distinguish true causal or biologically meaningful candidates from indirect or context-dependent signals, and (2) mechanistic studies that explain how validated genes or regulatory features influence cellular and molecular processes related to addiction.

What kinds of scientific candidates are within scope?

Projects can focus on candidate genes, gene variants, epigenetic marks, and non-coding RNA signals that have been implicated by prior large-scale genetic or genomic research in drug addiction.

What does "functional validation" mean in the context of this FOA?

Functional validation refers to studies designed to test whether a candidate genetic or genomic finding has a real biological effect relevant to addiction. Examples described in the FOA include confirming whether a gene variant changes gene function, whether an epigenetic feature alters gene expression in addiction-relevant tissues, or whether a non-coding RNA plays a regulatory role tied to addiction-related processes.

What does "mechanistic work" mean here?

Mechanistic work means mapping the molecular and cellular pathways through which validated genes, variants, epigenetic features, or non-coding RNAs influence addiction-relevant outcomes (for example, processes connected to drug exposure, withdrawal, craving, or relapse-related behaviors).

Are studies involving non-coding RNAs included?

Yes. Non-coding RNAs are explicitly included as a major scientific focus alongside functional genetics and epigenetics.

What addiction-related outcomes or processes are mentioned as relevant?

The FOA mentions regulatory roles tied to drug exposure, withdrawal, craving, and relapse-related behaviors as examples of addiction-relevant processes.

Does the FOA allow research on genes with unexpected connections to addiction?

Yes. The FOA notes interest in genes with "unanticipated" roles, meaning it is open to findings that connect addiction biology to pathways not traditionally linked to substance use disorders, as long as the pathway and its relationship to addiction-relevant outcomes are clarified.

What grant mechanism does this opportunity use?

This opportunity uses the NIH Small Research Grant (R03) mechanism.

What is the R03 mechanism intended for, according to the FOA?

The R03 is intended for smaller, tightly scoped projects that can be completed relatively quickly with limited resources.

What types of projects does the FOA say are a good fit for an R03?

The FOA highlights pilot or feasibility studies that generate preliminary evidence, secondary analyses of existing datasets, small self-contained research projects, and efforts to develop or refine research methods or technologies that enable functional genomic work in addiction.

Is this opportunity focused on large-scale gene discovery?

No. The emphasis is on moving beyond discovery and association to functional validation and mechanism.

Are secondary analyses of existing datasets allowed?

Yes. The FOA explicitly notes that secondary analyses of existing datasets are among the types of work the R03 is meant to support.

Does this FOA support method or technology development?

Yes. It includes efforts to develop or refine research methods or technologies that enable functional genomic work in addiction.

Are there companion announcements with the same scientific scope?

Yes. The FOA runs in parallel with two companion announcements of the same scientific scope but different grant sizes: PA-11-033 (R01 mechanism) and PA-11-034 (R21 mechanism).

How do the companion FOAs differ from this one?

They differ by grant mechanism and typical project scale: R01 is typically for larger, longer-term projects, while R21 is often used for exploratory or developmental projects. This FOA (R03) is for smaller, tightly scoped studies.

Is there a cost sharing or matching requirement?

No. The opportunity states there is no cost sharing or matching requirement.

When was this FOA posted and created?

It was posted and created on November 16, 2010.

What were the closing dates for applications?

The original and final closing date listed is January 7, 2014.

Is this FOA still open?

No. The announcement was archived on February 7, 2014, and the final closing date was January 7, 2014.

What is the broad subject area or category for this opportunity?

It is categorized under education and health.

Who is eligible to apply?

Eligibility is broad and includes many domestic and non-domestic organizations, including various government entities, higher education institutions, nonprofits (with or without 501(c)(3) status), tribal governments and organizations, for-profit organizations (including small businesses), and a range of mission-specific institutions such as HBCUs and Hispanic-serving institutions, as well as U.S. territories or possessions. Foreign (non-U.S.) entities are also listed as eligible.

Are foreign (non-U.S.) organizations eligible?

Yes. "Non-domestic (non U.S.) entities" are listed as eligible applicants.

Are for-profit organizations eligible to apply?

Yes. For-profit organizations other than small businesses and small businesses are both listed among eligible applicants.

Are nonprofits without 501(c)(3) status eligible?

Yes. The eligibility list includes nonprofits with or without 501(c)(3) status.

Are universities and colleges eligible?

Yes. Eligibility includes public and state-controlled institutions of higher education and private institutions of higher education, as well as several categories of minority-serving and tribally controlled institutions.

Are government entities eligible (state, county, city, districts)?

Yes. Eligible applicants include state, county, city, township, and special district governments, as well as independent school districts, and public and Indian housing authorities.

Are tribal governments and tribal organizations eligible?

Yes. Eligibility includes federally recognized tribal governments, other tribal governments, and tribal organizations.

Where can applicants find the official FOA details?

The FOA points to the archived NIH program announcement page at http://grants.nih.gov/grants/guide/pa-files/PA-11-035.html.

Who should be contacted for access or linking issues related to the FOA page?

The FOA provides NIH Office of Extramural Research webmaster contact information for access or linking issues: FBOWebmaster@OD.NIH.GOV.